← Back to Clinical Trials
Recruiting NCT04646252

NCT04646252 The Role of Glycocalyx Integrity in the Primary Prevention of Major Cardiovascular Events

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04646252
Status Recruiting
Phase
Sponsor University of Athens
Condition Endothelial Dysfunction
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2013-01-10
Primary Completion 2026-06-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Perfused Boundary Region of sublingual microvessels

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2013-01-10 with a primary completion date of 2026-06-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The researchers intend to recruit individuals who are referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital, Athens According to institutional protocols, a detailed medical history for atherosclerotic risk factors and current medication is recorded and a baseline clinical examination is performed. Moreover fasting blood samples are drawn to diagnose the presence of diabetes mellitus and hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are revaluated at one month and then followed up according to the attending physician's instructions. Pulse wave velocity and the rest pulse wave analysis parameters were also calculated to determine the additive predictive value for cardiovascular events beyond SCORE2. All subjects are followed up for adverse events (death, stroke, myocardial infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic contact and planned appointment at the outpatient clinic.

Eligibility Criteria

Inclusion Criteria: We recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital. Exclusion Criteria: * History of Coronary artery disease, * History of Peripheral Arterial Disease, * History of Heart failure * History of Stroke * hepatic failure * renal failure, * active neoplasia * poorly controlled DM, defined as Hba1C\>7%

Contact & Investigator

Central Contact

IGNATIOS IKONOMIDIS

✉ ignoik@gmail.com

📞 +30 2105832192

Principal Investigator

IGNATIOS IKONOMIDIS, PROFESSOR

PRINCIPAL INVESTIGATOR

National and Kapodistrian University of Athens

Frequently Asked Questions

Who can join the NCT04646252 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Endothelial Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04646252 currently recruiting?

Yes, NCT04646252 is actively recruiting participants. Contact the research team at ignoik@gmail.com for enrollment information.

Where is the NCT04646252 trial being conducted?

This trial is being conducted at Athens, Greece.

Who is sponsoring the NCT04646252 clinical trial?

NCT04646252 is sponsored by University of Athens. The principal investigator is IGNATIOS IKONOMIDIS, PROFESSOR at National and Kapodistrian University of Athens. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology